BioSpace News Archive

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary, and musculoskeletal disorders with high unmet medical need, provided a business update and reported financial results for the quarter ended June 30, 2022.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, reported second quarter 2022 financial results and recent operational progress.

Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, reported second quarter financial results for the period ending June 30, 2022 and provided business updates.

Maravai LifeSciences Holdings, Inc., a global provider of life science reagents and services to researchers and biotech innovators, reported financial results for the second quarter ended June 30, 2022, together with other business updates.

AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reported financial results for the second quarter ended June 30, 2022.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced financial results for the second quarter of 2022, and associated Company developments.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and six months ended June 30, 2022.

Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a leading benefits management company specializing in fertility and family building benefits solutions, today announced its financial results for the three-month period ended June 30, 2022 (“the second quarter of 2022”) as compared to the three-month period ended June 30, 2021 (“the second quarter of 2021” or “the prior year period”).

Cognition Therapeutics, Inc. announced that Mary Hamby, Ph.D., vice president of research, presented results at the at Alzheimer’s Association International Conference of proteomic analysis of clinical biomarker data from the SPARC study of oral once-daily treatment with CT1812 in mild-to-moderate Alzheimer’s disease.

Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported financial results for the quarter ended June 30, 2022, and provided a business update.